Wall Street Zen Downgrades Smith & Nephew SNATS (NYSE:SNN) to Buy

Smith & Nephew SNATS (NYSE:SNN) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

Several other brokerages have also issued reports on SNN. Kepler Capital Markets upgraded shares of Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Royal Bank Of Canada downgraded shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Finally, Canaccord Genuity Group reduced their price objective on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a research note on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $35.75.

Smith & Nephew SNATS Stock Performance

SNN stock opened at $36.10 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The business’s 50-day moving average is $33.77 and its two-hundred day moving average is $34.94. Smith & Nephew SNATS has a fifty-two week low of $23.91 and a fifty-two week high of $38.79.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SNN. Garner Asset Management Corp purchased a new stake in Smith & Nephew SNATS in the 4th quarter worth $27,000. Arax Advisory Partners boosted its stake in shares of Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 569 shares during the period. Advisors Asset Management Inc. purchased a new stake in shares of Smith & Nephew SNATS during the fourth quarter worth about $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Smith & Nephew SNATS during the third quarter worth about $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Smith & Nephew SNATS during the 4th quarter valued at approximately $43,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.